Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 432-440

  Murai, Akira ^a   Abe, Masayoshi ^a   Hayashi, Yuri ^a   Sakata, Noriyuki ^a   Katsuragi, Takeshi ^a   Tanaka, Keiichi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MONTELUKAST; OVALBUMIN; PEPTIDOLEUKOTRIENE;

AIRWAY DYNAMICS; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS MUCOSA; CELL INFILTRATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INHIBITION; DRUG MECHANISM; INFLAMMATORY CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETATES; AIRWAY RESISTANCE; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BILE; BRONCHOALVEOLAR LAVAGE FLUID; CYSTEINE; HYPERSENSITIVITY; LEUKOCYTE COUNT; LEUKOTRIENE A4; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LUNG; METHYLPREDNISOLONE; QUINOLINES; RATS; RATS, INBRED BN; RECEPTORS, LEUKOTRIENE;

EID: 13244292325     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.074922     Document Type: Article

References (40)

1. Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, Katsuragi T, and Okada H (2001) Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 167:4651-4660.
2. Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94:557-572.
3. Barnes PJ and Adcock IM (2003) How do corticosteroids work in asthma? Ann Intern Med 139:359-370.
4. Blain JF and Sirois P (2000) Involvement of LTD4 in allergic pulmonary inflammation in mice: modulation by cysLT1 antagonist MK-571. Prostaglandins Leukot Essent Fatty Acids 62:361-368.
5. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al. (1990) Eosinophilic inflammation in asthma. N Engl J Med 323:1033-1039.
6. Busse W (1998) The role and contribution of leukotrienes in asthma. Ann Allergy Asthma Immunol 81:17-19.
7. Busse WW and Lemanske RF Jr (2001) Asthma. N Engl J Med 344:350-362.
8. Busse WW and Rosenwasser LJ (2003) Mechanisms of asthma. J Allergy Clin Immunol 111:S799-S804.
9. Colamorea T, Di Paola R, Macchia F, Guerrese MC, Tursi A, Butterfield JH, Caiaffa MF, Haeggstrom JZ, and Macchia L (1999) 5-Lipoxygenase upregulation by dexamethasone in human mast cells. Biochem Biophys Res Commun 265:617-624.
10. Coles SJ, Neill KH, Reid LM, Austen KF, Nii Y, Corey EJ, and Lewis RA (1983) Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 25:155-170.
11. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA, and Samuelsson B (1981) Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78:3887-3891.
12. Dahlen SE, Hedqvist P, Hammarstrom S, and Samuelsson B (1980) Leukotrienes are potent constrictors of human bronchi. Nature (Lond) 288:484-486.
13. Drazen JM, Israel E, and O'Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206.
14. Fregonese L, Silvestri M, Sabatini F, and Rossi GA (2002) Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 32:745-750.
15. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK, Jones F, Eriksen P, Tien YT, Jonas M, et al. (1996) The importance of leukotrienes in airway inflammation in a mouse model of asthma. J Exp Med 184:1483-1494.
16. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P, et al. (1995) Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 73:191-201.
17. Karin M (1998) New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487-490.
18. Kodani M, Sakata N, Takano Y, Kamiya H, Katsuragi T, Hugli TE, and Abe M (2000) Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes. Immunopharmacology 49:263-274.
19. Kumlin M and Dahlen SE (1990) Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim Biophys Acta 1044:201-210.
20. 4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990.
21. Leff AR (2001) Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 52:1-14.
22. Leick-Maldonado EA, Kay FU, Leonhardt MC, Kasahara DI, Prado CM, Fernandes FT, Martins MA, and Tiberio IF (2004) Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in an experimental model of chronic airway inflammation in guinea-pigs. Clin Exp Allergy 34:145-152.
23. 4. J Biol Chem 263:174-181.
24. Maekawa A, Austen KF, and Kanaoka Y (2002) Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277:20820-20824.
25. Muñoz NM, Douglas I, Mayer D, Herrnreiter A, Zhu X, and Leff AR (1997) Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 155:1398-1403.
26. Nagy L, Lee TH, and Kay AB (1982) Neutrophil chemotactic activity in antigen-induced late asthmatic reactions. N Engl J Med 306:497-501.
27. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, and Sakamoto T (1998) Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 53:835-841.
28. National Institutes of Health/World Health Organization (2002) Global strategy for asthma management and prevention. NIH Publication No. 02-3659. Department of Health and Human Services, Washington, DC.
29. Naureckas ET and Solway J (2001) Clinical practice. Mild asthma. N Engl J Med 345:1257-1262.
30. 4 in rats. Am J Respir Crit Care Med 151:1143-1150.
31. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, et al. (2003) Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58:211-216.
32. Ramires R, Caiaffa MF, Tursi A, Haeggström JZ, and Macchia L (2003) Inhibition of 5-lipoxygenase activity by montelukast. Requirement of cellular integrity, in the 8th International Conference of Eicosanoids & Other Bioactive Lipids in Cancer, Inflammation and Related Diseases (Honn KV ed) pp 90, 2003 Sept 7-10; Chicago, IL.
33. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, and Zhang J (1997) Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52:45-48.
34. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, and Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis and biological effects. Science (Wash DC) 237:1171-1176.
35. 4 synthesis in vivo and attenuation of the acute inflammatory response. Mol Cell Biol 21:5389-5395.
36. Smith LJ (1996) Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Arch Intern Med 156:2181-2189.
37. Tomari S, Shimoda T, Kawano T, Mitsuta K, Obase Y, Fukushima C, Matsuse H, and Kohno S (2001) Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 87:156-161.
38. Vachier I, Chavis C, Majori M, Farce M, Bousquet J, Godard P, and Chanez P (2001) Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma. J Allergy Clin Immunol 107:824-831.
39. Wu AY, Chik SC, Chan AW, Li Z, Tsang KW, and Li W (2003) Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy 33:359-366.
40. Yu W, Xu L, Martin JG, and Powell WS (1995) Cellular infiltration and eicosanoid synthesis in brown Norway rat lungs after allergen challenge. Am J Respir Cell Mol Biol 13:477-486.